Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev
Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.
How this was made
The 30-second read
Why it matters
The disclosed royalty split and the plan to lead a veterinary development program via a joint venture provide a tangible new commercial angle that can attract speculative interest and momentum flows.
Market read
Traders are reacting to a fresh SEC filing that expands CannEpil’s exclusive license into veterinary medicine, alongside a stated veterinary development JV.
What to watch
The article provides no clinical or regulatory milestones, no timeline for the veterinary JV, and no confirmation of commercialization traction, which can cap upside if details disappoint.
Background
Splash Beverage Group is expanding its exclusive CannEpil global license to cover veterinary applications, adding companion-animal oncology and chronic pain use cases.
Ticker impact
SBEV shares jumped 64% after hours after an SEC filing said it expanded CannEpil’s exclusive global license to include veterinary applications.
Likely continued elevated volatility and momentum trading near-term, with follow-through dependent on additional JV details and commercialization timelines.
The article ties the after-hours surge to a specific SEC filing and adds concrete economics (10% royalty veterinary, 15% human) plus a stated JV being finalized, which traders can price immediately even without revenue guidance.
Market effects
Highlights incremental monetization pathways for cannabinoid drug platforms via veterinary indications, potentially supporting sentiment toward similar pre-commercial biotech/cannabinoid licensors.
No clear regional market linkage beyond Florida-based issuer context.
Limited global read-through; the catalyst is company-specific and tied to Australia-linked clinical-stage partner expansion.
Counterpoint
A 64% move in a microcap can be driven by thin-liquidity momentum, and the veterinary license expansion may not translate into near-term revenue.
Key entities
- companySplash Beverage Group Inc.
NYSE-listed issuer whose CannEpil license was expanded to veterinary applications.
- companyArgent BioPharma Limited
Australian clinical-stage biopharmaceutical company that received the expanded license scope in the SEC filing.
- productCannEpil
Cannabinoid drug platform whose exclusive global license was expanded to veterinary applications.
- personBrady Cobb
Interim CEO quoted on the value broadening from human to veterinary markets.
